uMotif and ActiGraph partner to deliver unmatched patient centric solutions

With this partnership, sponsors have the confidence of working with two best-in class technology providers who enable them to capture massive volumes of high-quality data by truly understanding what it means to engage patients

PENSACOLA, FL and BOSTON, MA – February 7, 2023 — uMotif – one of the clinical trial technology market’s fastest growing companies – and ActiGraph, a pioneer and leading provider of wearable remote monitoring technology, announced a partnership to make clinical trials more patient-centric and lower burden for participants. The partnership will leverage uMotif’s platform, which streamlines patient engagement and data collection, and ActiGraph’s leading expertise in clinical-grade wearable technology. The result will be a seamless, patient-centered solution for clinical research.

ActiGraph invited uMotif to join its Accelerant™ Partner Program because of uMotif’s unique focus on the patient experience. uMotif’s patient-first approach is delivering greater than 90% eCOA/ePRO compliance in both clinical trials and real-world studies – providing more and better-quality subjective data to sites, sponsors and CROs. Built by global experts in consumer design, clinical research technology and patient-first healthcare, the uMotif platform delivers new innovation in eCOA/ePRO.

By working together, the combined uMotif and ActiGraph solution will provide a more seamless, simple and engaging patient experience for any research study. Sponsors are increasingly focused on making trials more patient-centric, particularly those adopting hybrid and decentralized designs and capturing a range of data from patients, sensors and devices. New study designs can add complexity and burden for patients, sites and CROs, which is compounded by the need to work with multiple systems. uMotif’s and ActiGraph’s unique expertise and design-led approach provides a highly engaging and patient-friendly solution to capture both subjective ePRO and objective device data through a single experience.

Putting patients first is in uMotif’s DNA. The company’s experience over the past 10 years has proven that a patient-centered approach is vital to delivering effective studies at pace and scale, with unrivaled volumes of quality data. uMotif studies have engaged thousands of participants who have captured millions of data points for published research.  The new partnership with ActiGraph allows sponsors to capture clinical-grade actigraphy data alongside validated, patient-friendly eCOA/ePRO instruments.

uMotif CEO Steve Rosenberg (LinkedIn) said, “We’re delighted to partner with ActiGraph.  Our eCOA/ePRO solutions combined with ActiGraph’s wearables and science-based algorithms and services are a big step forward in putting patients’ comfort and convenience at the center of research, so we can collect massive amounts of quality data while making their lives a bit easier.” 

ActiGraph CEO Jeremy Wyatt (LinkedIn) said, “Working with partners like uMotif makes the ActiGraph experience better for patients and clinicians. We are excited to collaborate on a combined solution that will help bring new treatments to market faster than ever.”

About ActiGraph

ActiGraph is pioneering the digital transformation of clinical research. ActiGraph provides end-to-end digital health technology (DHT) solutions by integrating and operationalizing the best hardware, software, and algorithms to generate reliable evidence and get the right treatments to the right patients, faster. ActiGraph’s medical-grade wearable technology platform has been used to capture real-world, continuous digital measures of activity, sleep, and mobility for nearly 250 industry-sponsored clinical trials and thousands of academic research studies. Appearing in over 20,000 published scientific papers to date, ActiGraph is the most experienced and trusted wearable technology partner in the industry. For more information visit

About uMotif

The uMotif eCOA/ePRO platform delivers faster, quality clinical trials and real-world studies by putting patients at the core of research. Through cloud-hosting in the US, Europe and China, the GCP, 21 CFR Part 11 and GDPR-compliant platform supports any study or trial, from Clinical Phase I, II and III studies through to any type of decentralized or virtual real-world Study. For more information visit